Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes

Introduction: Although guidelines exist for appropriate use of chemotherapy in the metastatic setting based on performance status, such recommendations are less readily available for immune checkpoint inhibitors (ICIs). We sought to determine whether there is a relationship between Eastern Cooperati...

Full description

Bibliographic Details
Main Authors: Leah Wells, Michael Cerniglia, Sarah Hall, Audrey C. Jost, Gregory Britt
Format: Article
Language:English
Published: Innovative Healthcare Institute 2022-05-01
Series:Journal of Immunotherapy and Precision Oncology
Subjects:
immunotherapy
ecog
performance status
Online Access:https://theijpt.org/doi/pdf/10.36401/JIPO-22-3

Similar Items

Similar Items